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Peripheral T-cell lymphomas (PTCLs) represent account for less than 15% of all 
non-Hodgkin lymphomas worldwide. In the current WHO classification scheme, 
more than 25 types of T-cell neoplasms are listed (Table 1)1. Considering the 
non-cutaneous T-cell lymphomas, despite substantial geographic variations in 
the incidence and the subtype prevalence, a few entities – essentially those 
presenting as nodal diseases - are relatively common and account for the 
majority of the cases while extranodal entiites are far less common or 
distinctively rare. Here, we will review the clinico-pathological features of breast 
implant-associated anaplastic large cell lymphoma intestinal T-cell neoplasms, 
with a focus on the recent advances gained in their molecular biology and 
pathogenesis. 
Breast implant-associated anaplastic large cell 
lymphoma 
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a very 
rare form of T-cell lymphoma that arises in association with breast implants. BIA-
ALCL was introduced as a new provisional disease entity in the recently revised 
WHO classification of lymphoid malignancies, distinct from the other types of 
ALCLs already recognized (anaplastic lymphoma kinase (ALK)-positive and ALK-
negative ALCL, and primary cutaneous ALCL)1.  
 
Epidemiology 
Since the first case was described in 1997, more than 500 cases of BIA-ALCL 
have been reported in the literature worldwide. An increasing number of 
dioagnoses were recorded over the recent years reflecting a substantial increase 
in recognition and awareness of the disease.  Notwithstanding these trends, the 
incidence of BIA-ALCL remains very low. Primary breast lymphomas are 
represent 1-2% of all non-Hodgkin lymphomas, with most cases diagnosed as 
diffuse large B-cell lymphomas, follicular or marginal zone B-cell lymphomas. 
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Among more than 400 breast lymphomas accumulated between 2010 and 2018 
in the French lymphoma network, BIA-ALCL represented 10% of the diagnoses2. 
Taking into consideration the very large number of women with breast 
implants over the world, the individual risk of BIA-ALCL is very small. A recent 
population-based case-control study based on the pathology registry in the 
Netherlands established that that BI are associated with a markedly increased 
risk (400 times) of developing ALCL, but the absolute cumulative risk is 
estimated to one case for every 50'000 women with BI by the age of 50 years, 
and one per 7’000 by the age of 752. In another study based on US cases, the 




The mean age at diagnosis is in the 50s. Approximately 60% of women who 
develop BIA-ALCL had implants for cosmetic reasons and 40% had implants for 
reconstructive purposes after surgery for breast cancer. BIA-ALCL has also been 
reported in three trangender male to female indivisuals. The median time interval 
between implant insertion and lymphoma diagnosis is 8-9 years in different 
studies, but wide variations are observed. There is no significant difference in risk 
of developing BIA-ALCL according to the content of the implant (saline-filled 
versus silicone-filled). Conversely, the type of implant outer shell (smooth versus 
textured) appears to be relevant to risk, since no case of BIA-ALCL has yet been 
reported in patients who had smooth implants only, while both textured implants 
and smooth-shell implants with a prior textured implant history have been 
associated to BIA-ALCL. 
Most patients (70-80%) present as a periprosthetic effusion or “late 
seroma” (defined as an effusion occurring one year or more after initial surgery, a 
situation requiring further investigation as opposed to fluid collections arising 
shortly after surgery which are often benign and related to the procedure). A 
minority of cases (20-20%) present as a tumor mass infiltrating into the adjacent 
breast parenchyma, with or without an associated effusion. A subset of the 
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patients (around 20%) may present with regional lymphadenopathy, usually 
axillary, less frequently supra- or infra-clavicular4. However, lymphoma 
involvement is not proven by biopsy in all instances, so that the actual incidence 
of locoreginal nodal dissemination is likely lower. Uncommonly, cutanous lesions 
or B sympoms have been reported at presentation3. 
 
Morphology 
In cases presenting as an effusion, tumor cells may be identified in cytological 
samples obtained by fine needle aspiration of pericapsular fluid, or on 
capsulectomy specimens. On smears or cell blocks, the tumor cells are large and 
pleomorphic, with large nuclei and abundant cytoplasm. Cells with horseshoe-
shaped nuclei and a paranuclear cytoplasmic inclusion (“hallmark cells”) typically 
encountered in all forms of ALCL are also found in BIA-ALCL. The neoplastic 
cells may resemble Hodgkin-like Reed-Sternberg cells. In capsulectomy 
specimens, the tumor cells are embedded within a proteinaceous and fibrinous 
meshwork at the surface of the capsule, and may show varying degrees of 
capsular infiltration. In mass-forming lesions, the tumor cells infiltrate into the 
adjacent breast tissue and may be accompanied by a pronounced inflammatory 
component including prominent eosinophilia; necrosis is frequent and sclerosis is 
sometimes observed. Lymphomatous involvement of axillary lymph nodes is 
usually characterized by a low tumor burden and can feature a sinusoidal, 
perifollicular, diffuse or Hodgkin-like pattern, often associated to fibrosis4. 
 
Immunophenotype 
BIA-ALCL has an immunophenotype similar to that of systemic ALK-negative 
ALCL, and by definition virtually all neoplastic cells strongly positive for CD30 
and negative for ALK expression. CD15 is weakly positive in a significant 
proportion of cases. The expression of T-cell antigens is incomplete: CD43 is 
almost constantly expressed, CD4 expression is frequent and positivity for CD2 
and CD3 is more common than for CD5. CD8 expression is unusual but rare 
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cases may coexpress CD4 and CD8. An activated cytotoxic immunophenotype 
denoted by the expression of TIA-1, granzyme B and/or perforin. MUM1 is 
consistently positive. EBV is consistently negative. BIA-ALCL frequently 
expresses EMA but is negative for cytokeratins. 
 
Differential diagnoses 
The cytology and immunophenotyped of BIA-ALCL overlap with those of other 
systemic ALK-negative ALCL. Although rarely, systemic ALCL in patients with 
breast implants may manifest in the breast with a presentation mimicking BI-
ALCL. Likewise, primary cutaneous ALCL may involve the skin of the breast in 
women harboring breast implants. Staging and clinical history are therefore 
critical to establish the correct diagnosis. 
The infiltrative forms of BIA-ALCL may resemble Hodgkin lymphoma 
morphologically and both entities share a partially overlapping 
immunophenotype. However, Hodgkin lymphoma is distinctively rare in 
extarnodal localizations, and Hodgkin/Reed-Sternberg cells are usually negative 
for T-cell antigens while expressing an attenuated B-cell immunophenotype.  
Chronic inflammatory lesions in association to a breast implant may contain 
occasional CD30+ activated lymphoid cells and must be distinguished from BIA-
ALCL.  
 
Molecular and genetic features 
The molecular and genetic features of BIA-ALCL are summarized in Table 2. 
 
Antigen receptor genes 
The T-cell receptor genes (TRB and/or TRG) are rearranged in most cases. In a 
study where TRB deep amplicon sequencing was performed, VDJ family usage 
was not skewed, and analysis of the CDR3 sequences of the dominant clone did 
not predict affinity for known antigens. Interestingly, analysis of the sequences 
remaining after substraction of the malignant clone showed a restricted diversity 
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compared to blood repertoire5.  
 
Cytogenetics and copy number variations 
Three IL2-dependent TLBR (T-cell breast lymphoma) cell lines established from 
seroma-associated BI-ALCL had clonally abnormal complex karyotypes with a 
modal number of 47 chromosomes in one cell line (TLBR-1) and a hypertriploid 
pattern in TLBR-2 and TLBR-3 (reviewed in6). Fewer or no alterations numerical 
alterations have been identified in the few primary BI-ALCL samples examined 
so far, including the primary tumor from which TLR-1 was derived. In a recent 
study Blombery et al. reported on genome-wide copy number variations in 11 
effusion-based BIA-ALCL samples 5. This genomic assessment was derived from 
an hybridation-based NGS study of a large panel of hematologically-relevant 
genes. Detectable gains and/or losses were detected in 8/11 cases. Interestingly, 
a recurrent focal deletion on chromosome 1p corresponding to a minimal deleted 
region containing the haploinsiffisient tumor suppressor gene RPL5, which 
encodes a ribosomal protein forming part of the ribosomal 60S subunit, was 
observed in 5 cases. Other recurrent aberrations included PRDM1 loss in 3/11 
cases and focal high-level amplifications in TNFRSF11A which encodes RANK 
(Receptor Activator of Nuclear Factor kB) in 2 cases. Interestingly, membrane 
overexpression of RANK was demonstrated by immunohistochemistry in one of 
these cases. Other cases (one each) harbored gains involving MYC, P2RX7 and 
TMEM119, or KIT and PDGFRA. 
 
Sequence variants 
So far, a relatively small number of BIA-ALCL have been successfully analyzed 
by whole exome or, more commonly, targeted next generation sequencing5-7. 
The most recurrent finding consists of STAT3 activating mutations found overall 
in 13/34 cases, with a prevalence ranging from 20% to 64%. Recurrent mutations 
in other genes of the JAK-STAT pathway are also detected, including activating 
mutations in JAK1(4/29 cases) and inactivating mutations SOCS1, which 
encodes a negative regulator of the JAK-STAT pathway (2/16 cases). Mutations 
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in STAT5A or STAT5B have not been observed in any of 27 cases tested. 
Another interesting finding is the presence of somatic TP53 mutations in 
2/17cases, including in one patient who also had a germline TP53 mutation. A 
total of four women with known TP53 germline mutations have been reported to 
develop BIA-ALCL after reconstructive surgery for breast cancer, raising the 
question of a potentially increased risk of BIA-ALCLrelated to germline TP53 
alterations.  Other somatic mutations in BCOR, SETD2, PTPN, PRKCB or 
DNMT3 were reported in one case each.  Most genetic analyses have been 
carried out on cases which presented as effusions. In the study by Oishi et al. 
which comprised a large proportion cases with tumor cells infiltrating beyond the 
capsule (T4 stage), there was no enrichment for mutations in the tumoral cases, 
but the oversall frequency of mutations found in that study was low. In one case 
of BI-ALCL which presented as a solid tumor mass and recurred as an in situ 
lesion, dual gain-of-function mutations in JAK1 and STAT3 were identified in both 
specimens, a combination previously reported in systemic ALK-negative ALCLs6.  
 
Gene rearrangements 
Rearrangements of the IRF4/DUSP22 locus at 6p25 and of TP63 which are 
frequently observed in systemic or primary cutaneous ALCL, have not been 
found in any of the cases tested so far (0/46 and 0/37, respectively)2,6,7. In 
addition, no structural variants involving the TR genes have been identified5.  
 
Transcriptomic signature 
One study recently examined the gene expression signature of BIA-ALCL, in 
comparison to that of subsets of normal T cells, and of other ALCLs and T-cell 
lymphoma entities 8. It was found that BIA-ALCL cells have a transcriptional 
profile similar to activated CD4+ memory T cells, with an enrichment in 
transcripts encoding for IL17, RORC1 and in T regulatory genes, in association 
with a CD4+ CD25+ FoxP3+ immunophenoptype. Other characteristics of the 
BIA-ALCL signature include downregulation of the TCR signaling pathway, 
activation of STAT3, and upregulation of genes involved in cell motility, myeloid 
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differentiation and viral gene transcription. 
 
Pathogenesis 
The pathogenesis of BI-ALCL remains elusive, but several findings suggest that 
chronic inflammation elicited by silicone-derived products or bacteria adherent to 
the surface of the prosthesis paly a role in triggering lymphocyte activation, 
proliferation and expansion and ultimately malignant transformation2,9. In 
particular high bacterial loads of Ralstonia pickettii which may produce factors 
stimulating cytokine secretion have been evidenced at the surface of textured 
implants with BIA-ALCL. I line with the results of transcriptomic studies, culture 
experiments with BIA-ALCL native cells or cell lines have demonstrated a 
Th1/Th17 secretory profile, and cell lines show dependence on cytokines such as 
IL-, Il-6, and IL-10. Supervening mutations activating the JAK/STAT pathways 
and/or other genetic alterations likely represent an additional step in the 
trasformation process to a malignant monoclonal proliferation. Of note is that 
virtually all BIA-ALCL show evidence of STAT3 activation reflected by nuclear 
phospho-STAT3 expression, and BIA-ALCL derived cell lines are dependent oin 
STAT3 activation for their survival. 
 
Staging and outcome 
Most patients have excellent outcome, several studies have highlighted an 
association between the clinical pattern and disease aggressiveness, i.e. most 
cases presenting as a seroma appear to be cured with surgery alone and 
infrequently experience recurrences, while the presence of a solid tumor mass is 
an adverse prognostic factor2 . Importantly in patients with lymphoma confined to 
the fibrous periprosthetic capsule, complete surgical excision (total capsulectomy 
and breast implant removal) is an important determinant of a better overall 
survival and is the treatment of choice over partial excision, chemotherapy or 
radiation therapy only3. Lymph node involvement at initial presentation was found 
to correlate with an inferior overall survival 4. A detailed longitudinal analysis of 
patients who died of BI-ALCL showed locoregional dissemination of the disease 
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to the breast, locoregional lymph nodes, chest and mediastinum, but no 
systemic dissemination typical of other lymphomas. Therefore and because of 
the importance of complete surgical resection in patients with localized disease, it 
was suggested to use a TNM staging system similar in its principles to those 
applied to solid tumors, for evaluating BIA-ALCL3. (Table 3) 
Intestinal T-cell lymphomas 
About 15% of intestinal lymphomas are T-cell lymphomas. The two most 
common forms of primary intestinal lymphomas, derived from intraepithelial 
lymphocytes, formerly designated as enteropathy-associated T-cell lymphomas 
type I and type II, were renamed enteropathy-associated T-cell lymphoma  and 
monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), and represent 
5-8% of peripheral T-cell lymphomas1. Besides, the intestines can also be 
involved by virtually any type of T-cell lymphoma, especially EBV-associated 
ENKTL. Furthermore, peculiar and rare forms of indolent clonal gastrointestinal 
T-cell lymphoproliferative disorders have been recognized recently. 
Enteropathy-associated T-cell lymphoma and monomorphic epitheliotropic 
intestinal T-cell lymphoma  
Table 4 compares the main epidemiological, clinical, histolopathological, and 
genetic features of EATL and MEITL1 10. 
These lymphomas tend to occur in adults older than 50 years, with a slight 
male preponderance. Many cases present with acute abdominal symptoms due 
to perforation, obstruction, or bleeding. EATL patients, in addition, usually show 
signs of chronic malabsorption. EATL occurs in individuals with gluten-sensitive 
enteropathy and is more prevalent in Western populations. However, only 20-
73% of individuals are known to have celiac disease prior to the diagnosis of 
EATL. In some patients, the development of EATL is preceded by refractory 
celiac disease. The vast majority of patients have the celiac disease–associated 
HLADQA1*0501, DQB*0201 (HLA-DQ2) genotype and homozygosity for HLA-
DQ2 alleles (present in approximately 50% of cases) along with old age are 
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considered risk factors for developing EATL. MEITL is less common in Western 
populations and represents the most prevalent type of intestinal T-cell lymphoma 
in the Asian-Pacific region. Most studies suggest a lack of association with celiac 
disease. Both EATL and MEITL have a poor prognosis, with <20% five-year 
survival.  
Comparative genomic hybridization-based studies have shown that EATL 
and MEITL share common recurrent chromosomal imbalances and also have 
distinctive genetic alterations. Both are characterized by chromosome 9q gains 
and almost mutually exclusive losses at 16q12.1. Gain of chromosome 7 and 
losses involving 8p22-23.2, 16q21.1, 11q14.1- q14.2 and 9p21.2-p21.3 are also 
frequent in both diseases. Conversely, MEITL has more frequent gains of the 
MYC oncogene locus and less frequent gains of chromosomes 1q and 5q as 
compared with EATL. Additionally, loss of 3p21.31 is a recurrent aberration in 
MEITL but not in EATL.  
MEITL is characterized by highly recurrent alterations of the tumor 
suppressor gene SETD2 encoding a non-redundant H3K36-specific 
trimethyltransferase, in the vast majority of cases. SETD2 alterations are often 
biallelic, mainly due to loss-of-function mutations and/or loss of the 
corresponding locus (3p21.31) and consistently correlate with defective H3K36 
trimethylation11. Interestingly, SETD2 is also the most frequently mutated gene in 
hepatosplenic T-cell lymphoma, another rare form of highly aggressive T-cell 
lymphoma often observed from gamma-delta T cells and characterized by a 
sinusoidal infiltrate in the spleen, bone marrow and liver12.  In another study, 
SETD2 alterations were also identified in a smaller proportion of EATLs13.  Both 
EATL and MEITL demonstrate recurrent mutation-induced activation of the 
JAK/STAT pathway mainly due to STAT3/5B, JAK1/3 and SH2B3 mutations, and 
RAS pathway genetic aberrations (mutations in TP53, BRAF and KRAS).  MEITL 
also carries frequent mutations in GNAI2.  
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Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract 
This term designates clonal T-cell proliferations involving the gastrointestinal 
mucosa, with a relatively indolent clinical course1 14. Common presenting signs 
are chronic diarrhea, weight loss, abdominal pain, and/or rectal bleeding. 
Endoscopic findings include mucosal erythema, nodularity, erosions or small 
ulcers, and sometimes small polyps without mass lesions. Patients are adults, 
usually have multiple lesions along the gastro-intestinal tract, most commonly in 
the small intestines and colon. Some cases have evidence of extra-intestinal 
disease, with lymph node, liver or bone marrow infiltration. The etiology of these 
disorders is unknown, although some CD4+ LPDs occurred in individuals with an 
autoimmune or infectious disease. 
Mucosal biopsies reveal a variably dense, monotonous infiltrate of small 
lymphocytes that show little or no atypia, expanding the lamina propria and 
displacing the epithelial structures. The infiltrate is composed of CD3+ T cells, 
either CD4+ (more commonly) or CD8+, and in rare instances CD4-/CD8- or 
CD4+/CD8+. CD8-positive cases display a cytotoxic profile, and some cases 
show downregulation or loss of CD5 and/or CD7 expression. The Ki-67 
proliferation index is low (<10%). The genetic basis of these LPDs is poorly 
understood. Non-recurrent chromosome copy number changes have been 
identified by array-based approaches. STAT3 mutations (or evidence of STAT3 
activation) were not observed in a series largely comprising CD8+ LPDs. 
Recently, however, recurrent STAT3-JAK2 fusions have been identified by next-
generation sequencing and FISH analysis in 4 of 5 CD4+ LPDs15.  
The differential diagnosis includes on one hand benign conditions, such as 
celiac disease and inflammatory bowel disease, and on the other hand T-cell 
lymphomas. Appropriate diagnosis of these indolent T-cell lymphoproliferations is 
essential to avoid overtreatment with chemotherapy that results in unnecessary 
toxicity without significant benefit. Most patients are alive with persistent disease 
after several years of follow-up. However, complete remission occurs rarely and 
death due to disease progression or transformation has been documented in a 
few patients. 
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Table 1. Mature T-cell neoplasms (adapted from Swerdlow SH et al. WHO 2017)1  
 
Disseminated/leukemic 
T-cell prolymphocytic leukemia 
T-cell large granular lymphocytic leukemia 
Chronic lymphoproliferative disorder of NK cells* 
Aggressive NK-cell leukaemia 
Systemic EBV-positive T-cell lymphoma of childhood* 
Chronic active EBV infection of T- and NK-cell type, systemic form 
Adult T-cell leukemia/lymphoma 
 
Nodal 
Angioimmunoblastic T-cell lymphoma                                                   
Follicular T-cell lymphoma 
Nodal peripheral T-cell lymphoma with T follicular helper phenotype 
Anaplastic large cell lymphoma, ALK-positive 
Anaplastic large cell lymphoma, ALK-negative 
Peripheral T-cell lymphoma, not otherwise specified                                
 
Extranodal 
Extranodal NK/T-cell lymphoma, nasal type 
Enteropathy-associated T-cell lymphoma 
Monomorphic epitheliotropic intestinal T-cell lymphoma 
Indolent T-cell lymphoproliferative disorder of the gastro-intestinal tract* 
Hepatosplenic T-cell lymphoma 
Breast implant-associated anaplastic large cell lymphoma* 
 
Cutaneous 
Subcutaneous panniculitis-like T-cell lymphoma 
Mycosis fungoides 
Sezary syndrome 
Primary cutaneous CD30 + lymphoproliferative disorders 
    Lymhomatoid papulosis 
    Primary cutaneous anaplastic large cell lymphoma 
Primary cutaneous γδ T-cell lymphoma 
Rare primary cutaneous CD4+ or CD8+ entities* 
Hydroa vacciniforme-like lymphoproliferative disorder 
Severe mosquito bite allergy 
 





Table 2. Summary of genetic features of BIA-ALCL cases 
 
 
Copy number variations 
 Del(1p) (RPL5)  5/11 45% 
 PRDM1 loss   3/11 27% 
 TNFRSF11 amplification 2/11 18% 




ALK     0% 
DUSP22    0/46 0% 
TP63    0/37 0% 
TRA, TRB, TRG, TRD 0/11 0% 
 
Mutations 
 STAT3   13/34 38% 
STAT5A/5B   0/27 0% 
JAK1    4/29 14% 
JAK3    0/27 0% 
 SOCS1   2/16 13% 
 TP53    2/17 12% 
 Non-recurrent: BCOR, DNMT3, PTNP1, PRKCB 
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Table 3. Proposed TNM staging system for BIA-ALCL (adapted from Mehta-Shah 
N et al)3 
 
T: tumor extent 
T1   Confined to effusion or a layer on luminal side of the capsule 
T2   Early capsule infiltration 
T3   Cell aggregates or sheets infiltrating the capsule 
T4   Infiltration beyond rhe capsule 
Stage 
IA    T1 N0 M0 
IB    T2 N0 M0 
IC    T3 N0 M0 
IIA   T4 N0 M0 
IIB   T1-3 N1 M0 
III     T4 N1-2 M0 
IV     M1 
N: lymph node involvement 
N0   No lymph node invovlement 
N1   One lymph node involved 
N2   Multiple regional lymph nodes involved 
M: metastasis 
M0   No metastases 
M1   Spread to distant organs/sites 
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Table 4. Comparison of pathological and genetic features of EATL and MEITL 
 Enteropathy-associated T-
cell lymphoma  
Monomorphic epitheliotropic 
intestinal T-cell lymphoma 
(MEITL) 
Epidemiology Northern Europe, association 
with celiac disease (CD) 
HLA-DQ2/-DQ8 : >90% 
Celiac disease uncommon 
HLA-DQ2/-DQ8 : normal frequency 
Morphology Pleomorphic, medium to 




Monomorphic, small to medium size, 
epitheliotropic 
No inflammation, no necrosis 
Distant 
mucosa 
Enteropathy Increased intraepithelial 
lymphocytes, no atrophy 
Immuno-
phenotype 
CD3+, CD5-, CD8-/+, CD56- 
Frequently CD30+ 
Activated cytotoxic  
MATK+ < 40% of tumor cells 
CD3+, CD5-, CD8+/-, CD56+/- 
CD30- 
Activated cytotoxic  
MATK+ > 80% tumor cells 




Usually TCR silent  
or αβTCR>> γδTCR 
TCR usually expressed 




 +9q, -16q21.1  
 +8q24 (MYC)  
 +9q -16q21.1  
Epigenetics SETD2 mutations rare SETD2 inactivation (>90%) 
JAK/STAT 
pathway 
JAK1 mutations (20-50%) 
JAK3 mutations (10%) 
STAT3 mutations (20%) 
STAT5B mutations (rare) 
JAK1 mutations (10-20%) 
JAK3 mutations (35-50%) 
STAT3 mutations (10%) 
STAT5B mutations (50-65%) 
MAPK 
pathway 
KRAS NRAS BRAF 
mutations (20%) 




 GNAI2 mutations (24%) 





1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of 
haematopoietic and lymphoid tissues. Lyon: International Agency for 
Research on Cancer; 2017. 
2. Laurent C, Haioun C, Brousset P, Gaulard P. New insights into breast 
implant-associated anaplastic large cell lymphoma. Curr Opin Oncol. 
2018;30(5):292-300. 
3. Mehta-Shah N, Clemens MW, Horwitz SM. How I treat breast implant-
associated anaplastic large cell lymphoma. Blood. 2018;132(18):1889-
1898. 
4. Ferrufino-Schmidt MC, Medeiros LJ, Liu H, et al. Clinicopathologic 
Features and Prognostic Impact of Lymph Node Involvement in Patients 
With Breast Implant-associated Anaplastic Large Cell Lymphoma. Am J 
Surg Pathol. 2018;42(3):293-305. 
5. Blombery P, Thompson E, Ryland GL, et al. Frequent activating STAT3 
mutations and novel recurrent genomic abnormalities detected in breast 
implant-associated anaplastic large cell lymphoma. Oncotarget. 
2018;9(90):36126-36136. 
6. Letourneau A, Maerevoet M, Milowich D, et al. Dual JAK1 and STAT3 
mutations in a breast implant-associated anaplastic large cell lymphoma. 
Virchows Arch. 2018;473(4):505-511. 
7. Oishi N, Brody GS, Ketterling RP, et al. Genetic subtyping of breast 
implant-associated anaplastic large cell lymphoma. Blood. 
2018;132(5):544-547. 
8. Di Napoli A, De Cecco L, Piccaluga PP, et al. Transcriptional analysis 
distinguishes breast implant-associated anaplastic large cell lymphoma 
from other peripheral T-cell lymphomas. Mod Pathol. 2018. 
9. Quesada AE, Medeiros LJ, Clemens MW, Ferrufino-Schmidt MC, Pina-
Oviedo S, Miranda RN. Breast implant-associated anaplastic large cell 
lymphoma: a review. Mod Pathol. 2018. 
10. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. 
Histopathology. 2015;66(1):112-136. 
11. Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated T-cell 
lymphoma features a unique genomic profile with highly recurrent SETD2 
alterations. Nat Commun. 2016;7:12602. 
12. McKinney M, Moffitt AB, Gaulard P, et al. The Genetic Basis of 
Hepatosplenic T-cell Lymphoma. Cancer Discov. 2017;7(4):369-379. 
13. Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell 
lymphoma subtypes are characterized by loss of function of SETD2. J Exp 
Med. 2017;214(5):1371-1386. 
14. Matnani R, Ganapathi KA, Lewis SK, Green PH, Alobeid B, Bhagat G. 
Indolent T- and NK-cell lymphoproliferative disorders of the 
  17 
gastrointestinal tract: a review and update. Hematol Oncol. 2017;35(1):3-
16. 
15. Sharma A, Oishi N, Boddicker RL, et al. Recurrent STAT3-JAK2 fusions in 
indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. 
Blood. 2018;131(20):2262-2266. 
 

